Suicidal Ideation
Conditions
Keywords
treatment of acute suicidal ideation, ketamine, low-dose ketamine
Brief summary
The primary objective of this study is to assess the efficacy of ketamine versus a placebo for the short-term (at 72h, i.e. 24h after the last perfusion) relief of suicidal ideation, measured using the BSS hetero questionnaire, in patients hospitalized for suicide risk.
Detailed description
The secondary objectives of this study are to assess: A. The maintenance of medium-term effectiveness of ketamine on the resolution of suicidal ideation B. The evolution of the full spectrum of suicidality under ketamine compared to placebo C. The evolution of psychic and physical pain scores under ketamine compared to placebo D. The evolution of Beck Hopelessness score which is a predictor of long-term suicide risk, under ketamine compared to placebo E. The early antidepressant efficacy of ketamine in depressed, uni- or bipolar patients F. The somatic and psychological tolerance of ketamine G. An overall improvement in the clinical condition of the patient by the practitioner H. Creation of a biological collection for future ancillary studies dedicated to genetic analysis (microRNA and mRNA). I. The efficacy of ketamine versus a placebo for the short-term (at 72h, i.e. 24h after the last perfusion) relief of suicidal ideation, measured using the BSS self-report questionnaire, in patients hospitalized for suicide risk.
Interventions
OTHERBaseline evaluation
Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
DRUG1st perfusion of ketamine
A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
DRUG1st perfusion of saline
A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
OTHERFollow-up between perfusions
Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
DRUG2nd perfusion of ketamine
A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
DRUG2nd perfusion of saline
A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* French speaking patients freely hospitalized for prevention of suicide and who have a medium or high suicide risk score according to a MINI structured interview * The patient is able to understand how the study is carried out and the tests performed * The patient is deemed capable of giving his/her informed consent * The patient has been correctly informed * The patient must have given his/her informed and signed consent. * The patient must be insured or beneficiary of a health insurance plan. * Presence of suicidal ideation according to the SSI score (score \> 3) * Negative pregnancy test for women of childbearing age
Exclusion criteria
* The patient is participating in another interventional study * Within the past three months, the patient has participated in another interventional study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection * The patient is an adult under guardianship * The patient refuses to sign the consent * The patient is not able to understand the informed consent * Pregnancy or breastfeeding * History of schizophrenia or other psychotic disorders * Presence of psychotic symptoms at initial interview * Schizoid or schizotypic personality disorder * Positive urine screening for illicit substances, excluding cannabis * Substance dependence in the preceding month (excluding nicotine or caffeine) * Concomitant treatment with electroconvulsive therapy * Unstable somatic pathology * Clinically significant anomalies found during clinical examination, biological test or ECG * Non-stabilized hypertension or hypertension \> 180/100 * Known or suspected contra-indication for ketamine (includes interactions): hypersensitivity to ketamine, hypertension, class IV cardiac insufficiency, history of stroke, hepatic or cutaneous porphyria, history of intracranial hypertension
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BSSI score | Day 3 | A suicidal ideation score measured using the BSS (Beck et al. 1979) in its hetero questionnaire form ≤ 3 at 24 hours after the second infusion of ketamine or placebo (yes/no). A threshold ≤ 3 separates the resolution of suicidal ideas from their persistence (Holi et al. 2005; DiazGranados et al. 2010). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the full spectrum of suicidality using the CSSRS | Baseline (Day-2 to Day 0) | — |
| The BSSI score | Baseline (Day-2 to Day 0) | — |
| Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model | Baseline (Day-2 to Day 0) | — |
| Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model | Baseline (Day-2 to Day 0) | — |
| Evaluation of despair using the Beck Hopelessness Scale | Baseline (Day-2 to Day 0) | — |
| Evaluation of depression by the clinician (IDS-C30) | Baseline (Day-2 to Day 0) | — |
| The occurrence of a suicide attempt or a completed suicide (yes/no) | 6 weeks | — |
| Evaluation of psychic tolerance using the Young Mania Rating Scale (YMRS) | Baseline (Day-2 to Day 0) | — |
| Evaluation of psychic tolerance using the Brief Psychiatric Rating Scale (BPRS) | Baseline (Day-2 to Day 0) | — |
| Presence/absence of abnormal monitoring values throughout the study: hypertension | 6 weeks | Any abnormal hypertension, pulse oxymetry or cardiac frequency values observed during the study will be noted. |
| Presence/absence of abnormal monitoring values throughout the study: pulse oxymetry | 6 weeks | Any abnormal hypertension, pulse oxymetry or cardiac frequency values observed during the study will be noted. |
| Presence/absence of abnormal monitoring values throughout the study: cardiac frequency | 6 weeks | Any abnormal hypertension, pulse oxymetry or cardiac frequency values observed during the study will be noted. |
| Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) | Baseline (Day-2 to Day 0) | — |
| Evaluation of somatic tolerance of ketamine using the Patient Rated Inventory of Side Effects (PRISE) throughout follow-up | Baseline (Day-2 to Day 0) | — |
Countries
France
Outcome results
None listed